Salarius Pharmaceuticals Inc reports results for the quarter ended in December - Earnings Summary

Decoy Therapeutics

27/03/2023 13:56

* Salarius Pharmaceuticals Inc  SLRX.OQ  reported a
quarterly
adjusted loss of $2.83​​ per share for the quarter ended in
December. The mean expectation of two analysts for the quarter
was for a loss of $2.15 per share.
    * Reported revenue was zero​; analysts expected zero. 
    * Salarius Pharmaceuticals Inc's reported EPS for the
quarter was
a loss of $2.83​.
    * The mean earnings estimate of analysts was unchanged in
the last
three months.​ 
    * In the last 30 days, there have been no earnings estimate
revisions by analysts covering the company. 
    * Salarius Pharmaceuticals Inc shares had risen by 37.9%
this
quarter.
    * The company reported a quarterly loss of $6.37 million.
    * Wall Street's median 12-month price target for Salarius
Pharmaceuticals Inc is $70.50 
    * The current average analyst rating on the shares is
"strong buy"
and the breakdown of recommendations is 1 "strong buy" or
"buy," no "hold" and no "sell" or "strong sell." 

This summary was machine generated from LSEG Refinitiv data
March 27 at 12:56 p.m. UTC. ​All figures in US dollars unless
otherwise stated. QUARTER ENDING    ESTIMATE       ACTUAL         BEAT, MET,
                                                 MISSED
 Dec. 31 2022      -2.15          -2.83          Missed
 Sep. 30 2022      -2.55          -2.47          Beat
 Jun. 30 2022      -2.62          -2.25          Beat
 Mar. 31 2022      -2.25          -3.25          Missed